<DOC>
	<DOCNO>NCT01457950</DOCNO>
	<brief_summary>The purpose study determine denosumab effective increase bone mineral density lumbar spine Korean postmenopausal woman osteoporosis .</brief_summary>
	<brief_title>A Study Korean Postmenopausal Women With Osteoporosis Evaluate Efficacy Safety Denosumab</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>Ambulatory Korean postmenopausal woman osteoporosis great 5 year postmenopausal age 60 90 year old absolute bone mineral density value consistent Tscore le 2.5 great equal 4.0 either lumbar spine total hip , measure dual energy xray absorptiometry . Subjects Tscore le 4.0 high risk fracture exclude . previous current metabolic bone disease , Paget 's Cushing 's disease , hyperprolactinemia current hypo hyperparathyroidism hypo hyperthyroidism unless stable thyroid replacement therapy TSH level meet criteria rheumatoid arthritis cirrhosis liver unstable liver disease ALT AST great equal 2.0 time upper limit normal , alkaline phosphatase bilirubin great equal 1.5 time upper limit normal medication use treat osteoporosis , define type duration use , include IV oral bisphosphonates medication affect bone metabolism include parathyroid hormone derivative ; anabolic steroid testosterone ; glucocorticosteroids ; systemic hormone replacement therapy ; selective estrogen receptor modulators ; tibolone , calcitonin , calcitriol vitamin D derivatives ; bone active drug include anticonvulsives ( benzodiazepine ) heparin ; chronic systemic ketoconazole , androgen , ACTH , cinacalcet , aluminum , lithium , protease inhibitor , methotrexate , gonadotropinreleasing hormone agonist malignancy within 5 year except certain resected type malabsorption syndrome gastrointestinal disorder associate malabsorption abnormal calcium level vitamin D deficiency laboratory abnormality prevent subject complete study interfere interpretation study result severe renal impairment dialysis impair immune system subject take immunosuppressant oral dental condition include current past history osteomyelitis osteonecrosis jaw ; active dental jaw condition require oral surgery ; plan invasive dental procedure ; unhealed dental oral surgery disorder compromise ability subject give write informed consent comply study procedure physical psychiatric disorder prevent subject complete study interferes study result know tested positive HIV le two lumbar vertebra evaluable DXA measurement height , weight , girth may preclude accurate DXA measurement drug alcohol abuse within 12 month interferes understand complete study know sensitivity mammalian cellderived drug product use investigational drug device within 30 day enrollment currently receive investigational agent ( )</criteria>
	<gender>Female</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>denosumab</keyword>
	<keyword>Republic Korea</keyword>
	<keyword>dual energy x-ray absorptiometry</keyword>
</DOC>